Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

This document provides methods and materials involved in treating cancer. For example, methods and materials for using a BiPE that can include (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell), (b) an optional linker component, and (c) one or more molecules having the ability to bind to an antigen presenting cell (e.g., a human macrophage) to treat cancer are provided.

The present disclosure relates generally to immunoglobulin-related compositions such as antibodies or antigen binding fragments thereof that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof.

The present disclosure provides an antibody, antigen binding fragment thereof, or an antibody conjugate thereof, useful in methods for treatment or diagnosis of conditions characterized by the expression of PTGFRN. The antibodies or antigen binding fragments thereof may also be used in imaging or detecting cells that express PTGFRN.

The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.

An antibody having a higher function targeting a CD73 antigen, and more specifically, an antibody for cancer treatment having a higher activity. The antibody or a human-type antibody derivative that has a binding activity to a CD73 antigen and activates T cells having a toxic activity to cancer cells, and includes complementarity determining regions of any combination of heavy and light chains each having a specific amino acid sequence.

Provided are antibodies including antigen-binding fragment thereof that specifically recognizing Nerve Growth Factor NGF). Also provided are methods of making and using these antibodies.

The present disclosure relates to an antibody or an antigen-binding fragment thereof specifically binding to GRP94, and uses thereof. A GRP94 antibody or antigen-binding fragment thereof according to the present disclosure has very high specificity and affinity to GRP94, and excellent growth-inhibiting, infiltration-inhibiting, and angiogenesis-inhibiting effects on colorectal cancer cell lines, and thus can be useful as a composition for treating cancer, inhibiting cancer metastasis, and inhibiting angiogenesis.

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Tri-Specific Binding Molecule is preferably characterized in possessing binding domains that permit it to immunospecifically bind to: (1) an epitope of a first Cancer Antigen, (2) an epitope of a second Cancer Antigen, and (3) an epitope of a molecule that is expressed on the surface of an immune system effector cell, and are thus capable of localizing an immune system effector cell to a cell that expresses a Cancer Antigen, so as to thereby facilitate the killing of such cancer cell.